The OSUCCC – James is home to an internationally renowned center for hematologic malignancy treatment and research. Transdisciplinary teams of hematologists, oncologists, mid-level practitioners, researchers, nurses and other experts specialize in distinct hematologic malignancies, including:
- Acute myeloid leukemia (AML)
- Acute lymphoblastic leukemia (ALL)
- Blood and marrow transplantation
- Chronic lymphocytic leukemia (CLL)
- Hairy cell leukemia
- Myeloproliferative disorders
- Multiple myeloma
- Hodgkin lymphoma
- Non-Hodgkin lymphoma
Ohio State’s distinguished history in leukemia research began in 1958, when Dr. Bertha Bouroncle identified the cell responsible for hairy cell leukemia, a rare chronic leukemia.
Today, millions of dollars in research grants, including multiple grants from the National Cancer Institute and from the Leukemia and Lymphoma Society, support OSUCCC – James studies into how blood cancers develop and into identifying promising investigational treatments.
The OSUCCC – James is also one of only two comprehensive leukemia centers in the nation to have an NCI Specialized Program of Research Excellence (SPORE) grant.
Dozens of clinical trials under way at the OSUCCC – James enable us to provide patients with the latest advances in detecting and treating hematologic malignancies.